ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer

Part of paid clinical trials in Santa Monica, California.

Sponsor: Premiere Oncology
Study ID: NCT00404404
Phase: PHASE2
Status: Unknown

Conditions

Breast Cancer

Eligibility Criteria

Sex: FEMALE
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

bevacizumab — BIOLOGICAL
paclitaxel albumin-stabilized nanoparticle formulation — DRUG

Study Details

RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving ABI-007 together with bevacizumab may kill more tumor cells. PURPOSE: This phase II is studying how well giving ABI-007 together with bevacizumab works in treating women with recurrent or metastatic breast cancer.